Skip to main content

Towards precision medicine in Alzheimer's disease: deciphering genetic data to establish informative biomarkers.

Publication ,  Journal Article
Chiba-Falek, O; Lutz, MW
Published in: Expert Rev Precis Med Drug Dev
2017

INTRODUCTION: Developing biomarker tools for identification of individuals at high-risk for late-onset Alzheimer's disease (LOAD) is important for prognosis and early treatment. This review focuses on genetic factors and their potential role for precision medicine in LOAD. AREAS COVERED: APOEe4 is the strongest genetic risk factor for non-Mendelian LOAD, and the APOE-linkage disequilibrium (LD) region has produced the most significant association signal in multi-center genome-wide-association-studies (GWAS). Consideration of extended haplotypes in the APOE-LD region and specifically, non-coding variants in putative enhancer elements, such as the TOMM40-polyT, in-addition to the coding variants that comprise the APOE-genotypes, may be useful for predicting subjects at high-risk of developing LOAD and estimating age-of-onset of early disease-stage symptoms. A genetic-biomarker based on APOE-TOMM40-polyT haplotypes, and age is currently applied in a clinical trial for prevention/delay of LOAD onset. Additionally, we discuss LOAD-GWAS discoveries and the development of new genetic risk scores based on LOAD-GWAS findings other than the APOE-LD region. EXPERT COMMENTARY: Deciphering the precise causal genetic-variants within LOAD-GWAS regions will advance the development of genetic-biomarkers to complement and refine the APOE-LD region based prediction model. Collectively, the genetic-biomarkers will be translational for early diagnosis and enrichment of clinical trials with subjects at high-risk.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Rev Precis Med Drug Dev

DOI

ISSN

2380-8993

Publication Date

2017

Volume

2

Issue

1

Start / End Page

47 / 55

Location

England
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chiba-Falek, O., & Lutz, M. W. (2017). Towards precision medicine in Alzheimer's disease: deciphering genetic data to establish informative biomarkers. Expert Rev Precis Med Drug Dev, 2(1), 47–55. https://doi.org/10.1080/23808993.2017.1286227
Chiba-Falek, Ornit, and Michael W. Lutz. “Towards precision medicine in Alzheimer's disease: deciphering genetic data to establish informative biomarkers.Expert Rev Precis Med Drug Dev 2, no. 1 (2017): 47–55. https://doi.org/10.1080/23808993.2017.1286227.
Chiba-Falek O, Lutz MW. Towards precision medicine in Alzheimer's disease: deciphering genetic data to establish informative biomarkers. Expert Rev Precis Med Drug Dev. 2017;2(1):47–55.
Chiba-Falek, Ornit, and Michael W. Lutz. “Towards precision medicine in Alzheimer's disease: deciphering genetic data to establish informative biomarkers.Expert Rev Precis Med Drug Dev, vol. 2, no. 1, 2017, pp. 47–55. Pubmed, doi:10.1080/23808993.2017.1286227.
Chiba-Falek O, Lutz MW. Towards precision medicine in Alzheimer's disease: deciphering genetic data to establish informative biomarkers. Expert Rev Precis Med Drug Dev. 2017;2(1):47–55.

Published In

Expert Rev Precis Med Drug Dev

DOI

ISSN

2380-8993

Publication Date

2017

Volume

2

Issue

1

Start / End Page

47 / 55

Location

England